Grainger (GWW) reported better-than-expected first quarter results, primarily due to strong demand and better volumes in its US business. The company’s adjusted earnings rose 45% to $4.18 per share, beating street estimates. Sales for the quarter came in at $2.8 billion, up 9% compared to the prior-year period due to improved volumes. Operating margins improved 60 basis points to 12.1%.
Sales in the US segment rose 8% to $2.1 billion. Meanwhile, the Canadian business posted $20 million in operating loss due to declining sales and ongoing restructuring efforts. Other Businesses sales increased 18% compared to last year, primarily due to a 24% sales growth from its online business. The company expects the growth trend to continue from its online business, which would augur well to its bottom-line.
Branch closures continued in the first quarter. Total branches at the end of the first quarter stood at 480 compared to 500 at the end of last quarter. As expected, most of the closures (17 branches) were in Canada. The company ended the first quarter with 32 distribution centers.
Grainger is upbeat about the full-year results due to the improving volumes and strong demand for its products, besides the ongoing transformation efforts in the Canadian business.
The company has raised its sales and earnings forecast for 2018. It now expects sales growth of 5% to 8%, compared to 3% to 7% reported last quarter. Earnings are predicted to be between $14.30 and $15.30 per share vs $12.95 to $14.15 reported in the fourth quarter.
Grainger’s price reduction strategy to tackle competition from Amazon and its peers seem to be bearing fruit. On top of that, the company has reported volume growth due to strong demand in the Industrial sector for the past two quarters. Grainger’s share price has increased 29% in 2018, exceeding the 16% growth recorded by the US Industrial Index.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated